Jazz Pharmaceuticals has struck a deal to source two targeted cancer therapies from Redx Pharma. Redx will pocket $10 million upfront, with more to follow, in return for developing candidates against ...

It ain’t over ‘til it’s over and for Redx Pharma, it’s over. Redx and Jounce Therapeutics announced Monday morning that the two companies agreed to terminate their proposed business combination ...

For Redx Pharma Plc’s (AIM:REDX) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. REDX is ...

I am going to take a deep dive into Redx Pharma Plc’s (LON:REDX) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure of a company has ...

There’s significant change on the way at Jounce Therapeutics. The embattled clinical-stage company announced Wednesday afternoon that it is laying off more than half of its workforce as part of a ...

Shares in Redx Pharma were under pressure today following the announcement that it would not be advancing its cancer drug candidate RXC004 into phase 3 testing in biliary tract cancer, after it failed ...

Early stage drug development company Redx Pharma has been awarded a £4.7 million grant from the UK Government's Regional Growth Fund (RGF) to support the launch of a new £10.8 million research and ...

(Reuters) -British biotech firm Redx Pharma plc and U.S.-based Jounce Therapeutics Inc will merge to create a $425 million entity specialised in treating cancer and fibrotic disease. Redx shareholders ...

A $425 million proposed marriage between Redx Pharma of the UK and Jounce Therapeutics is on the rocks, just over a month after it was first announced. Jounce has instead thrown its lot in with ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Redx Pharma has returned to the land of the living. Last week, shares in the biotech group were reinstated on ...